- Filed
- Feb 11, 2026
- Period
- FY2025
- Fiscal year end
- 12/28
- Filings
- 1
10-K · latest 10
What Johnson & Johnson's 10-K filings say
- SEC EDGAR
10-K · FY2025
Filed · Fiscal year ends 12/28 · 12 signals
J&J to separate its Orthopaedics business within 18-24 months, starting October 2025
The planned separation of the Orthopaedics business will create a new, independent entity requiring its own IT infrastructure, ERP, HR, and other business systems.
J&J to separate its Orthopaedics business, targeting completion in 18-24 months.
This major divestiture, announced in October 2025, will require significant investment in legal, financial, and IT services to carve out the business unit.
J&J expects negative sales impact on STELARA (6.5% of revenue) from global biosimilar launches.
The company's second-largest product, STELARA, is facing imminent competition from biosimilars in the U.S.
6.5%
of total revenues from STELARA
J&J faces revenue loss for STELARA (6.5% of total revenue) due to biosimilar competition.
The company anticipates a significant negative impact on sales of its second-largest product, STELARA, as biosimilar versions launch globally.
6.5%
percentage of total fiscal 2025 revenue from STELARA
biosimilar manufacturers
New and complex regulations in the EU (NIS2, Cyber Resilience Act), US, and China are increasing compliance burdens and enforcement risks.
cybersecurity
J&J paid $2.4B in 2025 royalties to Genmab for its top drug, DARZALEX.
The company pays significant royalties (12-20% of net sales) for its largest product, which accounts for 15% of total revenue.
$2.4B
Royalty amounts paid to Genmab for fiscal 2025
15%
of total revenues from DARZALEX
Genmab A/S
J&J faces new compliance requirements from EU and China data privacy and AI regulations.
New regulations in the EU (NIS2, AI Act) and China are forcing J&J to make 'compliance developments or enhancements.' This signals a need for investment in new systems, processes, and technologies for data management, cybersecurity, and ethical AI governance to mitigate new enforcement risks.
AI
J&J acknowledges need for new compliance systems to address emerging AI regulations.
The company highlights that the global trend of regulating AI and generative AI will require 'compliance developments or enhancements,' signaling a need for investment in AI governance, ethics, privacy, and security solutions to mitigate risk.
Artificial Intelligence (AI)generative AI
J&J facing new enforcement risks from complex data privacy laws in the EU and China.
New regulations like NIS2, the AI Act in the EU, and broad data security laws in China are creating significant compliance challenges and enforcement risks, driving the need for enhanced data governance, cybersecurity, and cross-border data transfer solutions.
cybersecurity
J&J investing in digital and robotic technologies for its MedTech Surgery portfolio
The MedTech segment is actively developing and deploying digital and robotic technologies to improve surgical procedural consistency and efficiency.
robotics
Showing 10 of 12 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Johnson & Johnson with the Signal API
One POST /v1/companies/enrich call with jnj.com returns Johnson & Johnson 10-K signals (sec-10k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"jnj.com","signal_types":["sec-10k"],"limit":20}'Same industry
10-K at related companies
Questions about Johnson & Johnson 10-K
When did Johnson & Johnson file its latest 10-K?
What does Johnson & Johnson's latest 10-K say about restructuring?
Where can I find Johnson & Johnson's annual report?
Source. Annual reports (Form 10-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .